Akarsu, MesutÖnem, SonerTuran, İlkerAdalı, GupseAkdoğan, MeralAkyıldız, MuratAladağ, MuratBalaban, YaseminDanış, NilayDayangaç, MuratGençdal, GencoGökcan, HaleSertesen, ElifGürakar, MerveHarputluoğlu, MuratKabacam, GökhanKarademir, SedatKıyıcı, MuratIdılman, RamazanKarasu, Zeki2024-06-242024-06-242021-08-31https://doi.org/10.5152/tjg.2021.21608https://turkjgastroenterol.org/en/recommendations-for-hepatitis-b-immunoglobulin-and-antiviral-prophylaxis-against-hepatitis-b-recurrence-after-liver-transplantation-136804https://hdl.handle.net/11452/42254The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.eninfo:eu-repo/semantics/openAccessVirus recurrenceImmune globulinSurface-antigenNucleos(T)ide analogsViral-hepatitisPreventionManagementLamivudineEfficacyOutcomesHepatitis BLiver transplantationRecurrenceGastroenterology & hepatologyReview00070334660000171271932910.5152/tjg.2021.216082148-5607